This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Single gene defects causing NIDDM

Authoring team

The following gene defects have been associated with rare inherited forms of NIDDM:

  • insulin:
    • autosomal dominant
    • very rare
    • insulin produced is inactive
    • most insulin mutations do not cause diabetes

  • insulin receptor:
    • autosomal dominant or recessive
    • characterised by severe insulin resistance

  • glucokinase:
    • autosomal dominant
    • impairs insulin secretion
    • causes mild but early onset NIDDM (MODY 2)

  • HNF-1 alpha:
    • hepatocyte nuclear factor 1 alpha gene
    • autosomal dominant
    • rare & progressive early onset NIDDM (MODY 3)

  • HNF-4 alpha:
    • hepatocyte nuclear antigen 4 alpha gene
    • autosomal dominant
    • very rare & progressive early onset NIDDM (MODY 1)

  • mitochondrial leucine tRNA:
    • maternal inheritance
    • mutation at nucleotide 3243
    • impaired insulin secretion
    • account for up to 1% of all NIDDM patients
    • may be associated with deafness, MELAS and CEO

Reference:

  • O'Rahilly, S. (1997). Non-insulin dependent diabetes mellitus: the gathering storm. BMJ. 314, 955-9.
  • Johns, DR. (1996). The other human genome: mitochondrial DNA and disease. Nature Medicine, 2(10), 1065-8.

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.